Radioactive ligands for the prostate-specific membrane antigen (PSMA) are under
development for therapy of metastasized prostate cancer. Since PSMA expression is also …

Prostate-specific membrane antigen (PSMA) is a well-established target for nuclear imaging
and therapy of prostate cancer (PCa). Radiolabeled small-molecule PSMA inhibitors are …

Despite significant gains in the treatment of metastatic castration-resistant prostate cancer by
radioligands targeting prostate-specific membrane antigen (PSMA), 30% of patients never …

Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer, and
small-molecule radiopharmaceuticals targeting PSMA rapidly detect the location and extent …

Purpose: Prostate-specific membrane antigen (PSMA) targeting radioligands deliver
radiation to PSMA-expressing cells. However, the relationship between PSMA levels and …

Prostate-specific membrane antigen (PSMA) is a transmembrane protein commonly found
on the surface of late-stage and metastatic prostate cancer and a well-known imaging …

Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer.
Recently, we started the first-in-human treatment with an α-radionuclide–labeled PSMA …

Prostate specific membrane antigen (PSMA) has become a major focus point in the research
and development of prostate cancer (PCa) imaging and therapeutic strategies using …

Purpose: Prostate-specific membrane antigen (PSMA) is a cell surface protein that is
overexpressed in prostate cancer, including hormone-refractory and metastatic disease. Our …

The prostate-specific membrane antigen (PSMA) is an excellent target for theranostic
applications in prostate cancer. However, PSMA-targeted radioligand therapy can cause …